drugset / Trial / NCT04984577
Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.
Timeline
- Start
- 2021-11-15
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Edaravone | Unknown | 30 mg | Intravenous |
| Subject | Edaravone | Unknown | 50 mg | Intravenous |
| Subject | Taurine | Other / unclassified | 600 mg | Intravenous |
| Subject | Taurine | Other / unclassified | 1000 mg | Intravenous |